Veeda Clinical Research files DRHP for Rs 831 crore IPO
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has already embarked upon significant expansion in Turkey
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Subscribe To Our Newsletter & Stay Updated